Yan-na ZHANG, Yi-dong ZHOU, Feng MAO, Ru YAO, Qiang SUN. Prognostic Value of Progesterone Receptor and Ki-67 Combination in Hormone Receptor Positive Grade 2 Early-stage Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 539-545. doi: 10.3969/j.issn.1674-9081.2019.05.019
Citation: Yan-na ZHANG, Yi-dong ZHOU, Feng MAO, Ru YAO, Qiang SUN. Prognostic Value of Progesterone Receptor and Ki-67 Combination in Hormone Receptor Positive Grade 2 Early-stage Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 539-545. doi: 10.3969/j.issn.1674-9081.2019.05.019

Prognostic Value of Progesterone Receptor and Ki-67 Combination in Hormone Receptor Positive Grade 2 Early-stage Breast Cancer

doi: 10.3969/j.issn.1674-9081.2019.05.019
More Information
  • Corresponding author: SUN Qiang Tel: 86-10-69158703, E-mail:sunqiangpumc@sina.com
  • Received Date: 2018-01-16
  • Publish Date: 2019-09-30
  •   Objective  To evaluate the prognostic value of the combination of progesterone receptor (PR) and Ki-67 index in grade 2 breast cancer with positive hormone receptor (HR) and negative axillary lymph node.  Methods  The clinical and pathological data of patients with grade 2 breast cancer who underwent surgical treatment and 21 genes' recurrence score (RS) testing in the department of Breast Surgery, Peking Union Medical College Hospital from May 2012 to May 2017 were retrospectively analyzed. According to the 21 genes' RS, patients were divided into RS low-risk group (RS < 18), RS intermediate-risk group (18≤RS < 31), and RS high-risk group (RS≥31). At the same time, the combination of PR and Ki-67 index (PK) was set according to the expression of PR and Ki-67 index. The patients were divided into PK low-risk group (PR≥10% and Ki-67≤20%), PK high-risk group (PR < 10% and Ki-67>20%), and PK intermediate-risk group (non-high or low-risk group). The consistency of the PK combination and 21 genes' RS was analyzed and compared.  Results  A total of 389 patients who met the inclusive and exclusive criteria were enrolled in this study, including 247 patients in RS low-risk group (63.5%, 247/389), 115 in RS intermediate risk group (29.6%, 115/389), 27 in RS high-risk group (6.9%, 27/389), 248 in PK low-risk group (63.8%, 248/389), 125 in PK intermediate risk group (32.1%, 125/389), 16 in PK high-risk group (4.1%, 16/389). The predictive sensitivity of the recommended PK combination for RS low risk and high-risk group was 75.3% and 37.0%, respectively, with the positive predictive values of 75.0% and 62.5%, and the inconsistency of 0.4% and 6.3%, respectively. After a median follow-up of 40 months, the total incidence of locoregional recurrence (LRR) and distant metastasis (DM) in PK low, intermediate, and high-risk group was 3.6%, 7.2%, and 12.5%, respectively. The total incidence of LRR and DM in RS low, intermediate, and high-risk groups was 3.2%, 8.7%, and 7.4%, respectively. There was no significant difference between PK combination and RS (P=0.655).  Conclusion  The prognostic value of PK combination for HR-positive grade 2 early-stage breast cancer with negative axillary lymph nodes is comparable to that of the 21 genes' RS.
  • loading
  • [1] Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2016, 14:324-354. doi:  10.6004/jnccn.2016.0037
    [2] Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer:results from NSABP B-14 and NSABP B-20[J]. J Clin Oncol, 2010, 28:1677-1683. doi:  10.1200/JCO.2009.23.7610
    [3] Zhang YN, Zhou YD, Mao F, et al. Impact of the 21-Gene Recurrence Score Assay in adjuvant chemotherapy selection for node-negative, hormone receptor-positive breast cancer in the Chinese population[J]. Neoplasma, 2015, 62:658-665. doi:  10.4149/neo_2015_079
    [4] Toi M, Iwata H, Yamanaka T, et al. Clinical significance of the 21-gene signature(Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population[J]. Cancer, 2010, 116:3112-3118. doi:  10.1002/cncr.25206
    [5] Lee MH, Han W, Lee JE, et al. The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea[J]. Cancer Res Treat, 2015, 47:208-214. http://europepmc.org/articles/PMC4398124/
    [6] Henry NL, Braun TM, Ali HY, et al. Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry[J]. Cancer, 2017, 123:948-956. doi:  10.1002/cncr.30429
    [7] Zeng Y, Li Q, Qin T, et al. Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer:A Prospective Study[J]. Anticancer Res, 2017, 37:4539-4547. http://www.ncbi.nlm.nih.gov/pubmed/28739750
    [8] 张燕娜, 周易冬, 茅枫, 等. 21基因检测复发风险评分在激素受体阳性早期乳腺癌临床治疗和预后评估中的价值[J].中华肿瘤杂志, 2018, 2:110-114. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhzl201802006
    [9] Thakkar JP, Mehta DG. A review of an unfavorable subset of breast cancer:estrogen receptor positive progesterone receptor negative[J]. Oncologist, 2011, 16:276-285. doi:  10.1634/theoncologist.2010-0302
    [10] Prat A, Cheang MC, Martin M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer[J]. J Clin Oncol, 2013, 31:203-209. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5411e2931d23233da9ce5fe94600509c
    [11] Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24:2206-2223. doi:  10.1093/annonc/mdt303
    [12] Kurozumi S, Matsumoto H, Hayashi Y, et al. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index[J]. BMC Cancer, 2017, 17:354-362. doi:  10.1186/s12885-017-3331-4
    [13] Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immunol, 1984, 133:1710-1715. http://www.tandfonline.com/servlet/linkout?suffix=cit0008&dbid=8&doi=10.1080%2F2162402X.2015.1066062&key=6206131
    [14] Nishimura R, Osako T, Okumura Y, et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis[J]. Breast Cancer, 2010, 17:269-275. doi:  10.1007/s12282-009-0161-5
    [15] Honma N, Horii R, Iwase T, et al. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy[J]. Breast Cancer, 2015, 22:71-78. doi:  10.1007/s12282-013-0455-5
    [16] Curigliano G, Burstein HJ, P Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer:the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J]. Ann Oncol, 2017, 28:1700-1712. doi:  10.1093/annonc/mdx308
    [17] Varga Z, Diebold J, Dommann-Scherrer C, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast and Gynecopathologists[J]. PLoS One, 2012, 7:e37379. doi:  10.1371/journal.pone.0037379
    [18] Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histopa-thologic variables predict Oncotype DX recurrence score[J]. Mod Pathol, 2008, 21:1255-1261. http://www.nature.com/modpathol/journal/v21/n10/abs/modpathol200854a.html
    [19] Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer[J]. J Clin Oncol, 2011, 29:4273-4278. doi:  10.1200/JCO.2010.31.2835
    [20] Geradts J, Bean SM, Bentley RC, et al. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features[J]. Cancer Invest, 2010, 28:969-977. doi:  10.3109/07357907.2010.512600
    [21] Turner BM, Skinner KA, Tang P, et al. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score[J]. Mod Pathol, 2015, 28:921-931. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=fb2bfaca0f340dad9a678b4060cee5e8
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索


    Article Metrics

    Article views (404) PDF downloads(93) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint